[Skip to Content]
[Skip to Content Landing]
October 1987

Immunodeficiency-Associated Thrombocytopenic Purpura (IDTP)Response to Splenectomy

Author Affiliations

From the Departments of Surgery (Drs Schneider, Rayner, and Hohn) and Medicine (Dr Abrams), University of California—San Francisco.

Arch Surg. 1987;122(10):1175-1178. doi:10.1001/archsurg.1987.01400220085016

• Immunodeficiency-associated thrombocytopenic purpura (IDTP) is a feature of the acquired immunodeficiency syndrome—related complex. Current therapeutic modalities for IDTP include splenectomy and the administration of corticosteroids or other agents. Empiric treatment of IDTP has been analogous to that for immunologic thrombocytopenic purpura (ITP). The present report reviews 15 patients who underwent splenectomy for IDTP, demonstrates the successful use of surgical therapy, and defines our indications for splenectomy in the treatment of this disorder. Thirteen of 15 patients had initially failed to respond to steroid therapy. Fourteen patients (93%) initially responded to splenectomy, with platelet counts increasing to 150 × 109/L (150 000/mm3) or greater. A continuing complete response was achieved in nine patients (60%) following splenectomy. After postsurgical adjunctive therapy, durable remission was achieved in 73% (11/15) of the patients. Complications occurred in three patients, and there were no deaths. The mean follow-up was 12.4 months. Splenectomy may be performed in the treatment of IDTP with acceptable morbidity and likelihood of response.

(Arch Surg 1987;122:1175-1178)